Is there any impact of new drugs on the outcome of advanced NSCLC? An overview of the Southern Italy Cooperative Oncology Group Trials

Giuseppe Frasci, Nicola Panza, Giuseppe Comella, Giovanni Pacilio

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Lung cancer represents the major cause of cancer-related death in Europe and North America, accounting for 28% of all cancer deaths. Seventy to 80% of all lung cancers are non-small cell lung cancers (NSCLCs), and approximately 75% of these patients present with locally advanced or disseminated disease. Even though chemotherapy is now recommended in the majority of cases of unresectable NSCLC, it still fails to substantially modify the fate of these patients. In recent years, several active cytotoxic drugs (paclitaxel, docetaxel, vinorelbine, gemcitabine, and irinotecan) have been developed, showing an overall response rate (ORR)

Original languageEnglish
Pages (from-to)379-385
Number of pages7
JournalThe oncologist
Volume4
Issue number5
Publication statusPublished - 1999

Fingerprint

irinotecan
docetaxel
gemcitabine
Non-Small Cell Lung Carcinoma
Italy
Lung Neoplasms
North America
Paclitaxel
Pharmaceutical Preparations
Neoplasms
Drug Therapy
vinorelbine

Keywords

  • Chemotherapy trials
  • Cisplatin
  • Gemcitabine
  • NSCLC
  • Survival
  • Vinorelbine

ASJC Scopus subject areas

  • Cancer Research
  • Hematology

Cite this

Is there any impact of new drugs on the outcome of advanced NSCLC? An overview of the Southern Italy Cooperative Oncology Group Trials. / Frasci, Giuseppe; Panza, Nicola; Comella, Giuseppe; Pacilio, Giovanni.

In: The oncologist, Vol. 4, No. 5, 1999, p. 379-385.

Research output: Contribution to journalArticle

@article{6ac41f8f88564170a880aa9e58edd004,
title = "Is there any impact of new drugs on the outcome of advanced NSCLC? An overview of the Southern Italy Cooperative Oncology Group Trials",
abstract = "Lung cancer represents the major cause of cancer-related death in Europe and North America, accounting for 28{\%} of all cancer deaths. Seventy to 80{\%} of all lung cancers are non-small cell lung cancers (NSCLCs), and approximately 75{\%} of these patients present with locally advanced or disseminated disease. Even though chemotherapy is now recommended in the majority of cases of unresectable NSCLC, it still fails to substantially modify the fate of these patients. In recent years, several active cytotoxic drugs (paclitaxel, docetaxel, vinorelbine, gemcitabine, and irinotecan) have been developed, showing an overall response rate (ORR)",
keywords = "Chemotherapy trials, Cisplatin, Gemcitabine, NSCLC, Survival, Vinorelbine",
author = "Giuseppe Frasci and Nicola Panza and Giuseppe Comella and Giovanni Pacilio",
year = "1999",
language = "English",
volume = "4",
pages = "379--385",
journal = "Oncologist",
issn = "1083-7159",
publisher = "Wiley Blackwell",
number = "5",

}

TY - JOUR

T1 - Is there any impact of new drugs on the outcome of advanced NSCLC? An overview of the Southern Italy Cooperative Oncology Group Trials

AU - Frasci, Giuseppe

AU - Panza, Nicola

AU - Comella, Giuseppe

AU - Pacilio, Giovanni

PY - 1999

Y1 - 1999

N2 - Lung cancer represents the major cause of cancer-related death in Europe and North America, accounting for 28% of all cancer deaths. Seventy to 80% of all lung cancers are non-small cell lung cancers (NSCLCs), and approximately 75% of these patients present with locally advanced or disseminated disease. Even though chemotherapy is now recommended in the majority of cases of unresectable NSCLC, it still fails to substantially modify the fate of these patients. In recent years, several active cytotoxic drugs (paclitaxel, docetaxel, vinorelbine, gemcitabine, and irinotecan) have been developed, showing an overall response rate (ORR)

AB - Lung cancer represents the major cause of cancer-related death in Europe and North America, accounting for 28% of all cancer deaths. Seventy to 80% of all lung cancers are non-small cell lung cancers (NSCLCs), and approximately 75% of these patients present with locally advanced or disseminated disease. Even though chemotherapy is now recommended in the majority of cases of unresectable NSCLC, it still fails to substantially modify the fate of these patients. In recent years, several active cytotoxic drugs (paclitaxel, docetaxel, vinorelbine, gemcitabine, and irinotecan) have been developed, showing an overall response rate (ORR)

KW - Chemotherapy trials

KW - Cisplatin

KW - Gemcitabine

KW - NSCLC

KW - Survival

KW - Vinorelbine

UR - http://www.scopus.com/inward/record.url?scp=0032707827&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032707827&partnerID=8YFLogxK

M3 - Article

VL - 4

SP - 379

EP - 385

JO - Oncologist

JF - Oncologist

SN - 1083-7159

IS - 5

ER -